Investment Rating - The investment rating for the company is "Accumulate" (maintained) [3] Core Views - The company reported a revenue of 925 million yuan for 2024, representing a year-on-year growth of 9.1%, and a net profit attributable to shareholders of 317.8 million yuan, up 2.5% year-on-year [5] - The company is expected to achieve revenue of 1,033 million yuan in 2025, with a growth rate of 11.6%, and a net profit of 351.9 million yuan, reflecting a growth of 10.7% [5] - The company maintains a strong market position with over 80% market share in the domestic allergy treatment sector, and its product pipeline continues to expand [5] Financial Performance Summary - For 2024, the company achieved a gross margin of 95.16% and a stable expense ratio, with sales expense ratio at 39.06% [5] - The company’s R&D expenses for 2024 were 120 million yuan, accounting for 12.95% of revenue [5] - The earnings per share (EPS) for 2024 is projected to be 0.61 yuan, with a P/E ratio of 34.5 [3][5] Revenue and Profit Forecast - The forecasted revenues for 2025-2027 are 1,033 million yuan, 1,171 million yuan, and 1,354 million yuan, respectively, with corresponding year-on-year growth rates of 11.6%, 13.3%, and 15.7% [5] - The net profit forecast for the same period is 351.9 million yuan, 394.0 million yuan, and 450.2 million yuan, with growth rates of 10.7%, 12.0%, and 14.3% [5] Product Pipeline and Market Expansion - The company has successfully expanded its product matrix, with new products such as "Skin Prick Test Solutions" receiving approval for market entry [5] - The company is actively promoting its products in northern markets, leading to significant sales increases, particularly for the Dust Mite Drops and Artemisia Pollen Drops [5]

证券研究报告 | 公司动态点评 2025 年 06 月 04 日 闰土股份（002440.SZ） 活性染料业务向好推动公司业绩修复，公司产业链一体化优势逐步 显现-闰土股份 2024 年报及 2025 年一季报点评 | 财务指标 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业收入（百万元） | 5,588 | 5,695 | 5,811 | 5,925 | 6,072 | | 上升率 yoy（%） | -10.8 | 1.9 | 2.0 | 2.0 | 2.5 | | 归母净利润（百万元） | 46 | 213 | 283 | 338 | 347 | | 上升率 yoy（%） | -92.5 | 366.4 | 32.5 | 19.5 | 2.6 | | ROE（%） | 0.7 | 2.4 | 3.2 | 3.9 | 4.0 | | EPS 最新摊薄（元） | 0.04 | 0.19 | 0.25 | 0.30 | 0.31 | | P/E（倍） | 179.5 | 38.5 | 29. ...

| 财务指标 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业收入（百万元） | 5,588 | 5,695 | 5,811 | 5,925 | 6,072 | | 上升率 yoy（%） | -10.8 | 1.9 | 2.0 | 2.0 | 2.5 | | 归母净利润（百万元） | 46 | 213 | 283 | 338 | 347 | | 上升率 yoy（%） | -92.5 | 366.4 | 32.5 | 19.5 | 2.6 | | ROE（%） | 0.7 | 2.4 | 3.2 | 3.9 | 4.0 | | EPS 最新摊薄（元） | 0.04 | 0.19 | 0.25 | 0.30 | 0.31 | | P/E（倍） | 179.5 | 38.5 | 29.0 | 24.3 | 23.7 | | P/B（倍） | 0.9 | 0.9 | 0.9 | 0.9 | 0.8 | 证券研究报告 | 公司动态点评 2025 年 06 月 04 日 闰土股份（002440.SZ） ...

丰茂股份(301459) 公司研究/公司点评 对外投资落地，强化产能布局 ——公司对外投资公告点评 ◼ 事件描述 公司发布对外投资公告。公司拟与嘉兴高新技术产业开发区管理委员 会签订《嘉兴汽车零部件生产基地投资合作协议书》，拟在嘉兴高新技 术产业开发区购置土地，建设嘉兴汽车零部件生产基地项目。本项目 公司总投资额预计不超过人民币 15 亿元（最终投资金额以项目建设 实际投入为准）。 ◼ 核心观点 新建基地助力公司产能提升，强化产能布局 公司成长逻辑：立足主业传动系统，打造新领域增长极 汽车传统业务领域：1）出海竞争：公司泰国生产基地将于 2025 年正 式投产，主要面向东南亚及欧美市场。工厂将采用本地化供应与自动 化生产结合的模式，降低关税和物流成本，同时依托"米其林"品牌授 权，拓展海外经销商网络。泰国工厂的建成将提升公司国际市场份额。 2）进口替代：传动系统产品切入自主及合资品牌供应链，已配套上汽 通用五菱、上汽集团、一汽集团、吉利汽车等主流品牌多款车型，国 内整车配套市场逐步实现进口替代。 汽车新业务领域：1）产能扩张：2025 年，公司将在山东济南投建商 用车零部件生产基地，重点配套重汽、一汽、北汽福 ...

证券研究报告 公司研究 [Table_ReportType] 公司点评报告 [Table_StockAndRank] 阳光诺和(688621) 唐爱金 医药首席分析师 执业编号：S1500523080002 邮 箱：tangaijin@cindasc.com 贺鑫 医药行业分析师 执业编号：S1500524120003 邮 箱：hexin1@cindasc.com 信达证券股份有限公司 CINDA SECURITIES CO.,LTD 北京市西城区宣武门西大街甲127号金隅大厦B 座 邮编：100031 [Table_Title] STC007 二期临床数据读出，业务转型阶段把 握价值重估机遇 [Table_ReportDate] 2025 年 06 月 04 日 [Table_S 事件：2025ummar年y]5 月 29 日，公司公告全资子公司诺和晟泰自主研发的 STC007 注射液治疗腹部手术后的中、重度疼痛的 II 期临床试验达成预期目标。 点评： ➢ STC007 二期临床数据读出，具备较强的商业化潜力。 STC007 是诺和晟泰自主研发的化学 1 类新药，属于强效 KOR 激动剂， 与 KOR 受 ...

证券研究报告 公司研究 [Table_ReportType] 公司点评报告 [Table_StockAndRank] 阳光诺和(688621) 唐爱金 医药首席分析师 执业编号：S1500523080002 邮 箱：tangaijin@cindasc.com 贺鑫 医药行业分析师 执业编号：S1500524120003 邮 箱：hexin1@cindasc.com 信达证券股份有限公司 CINDA SECURITIES CO.,LTD 北京市西城区宣武门西大街甲127号金隅大厦B 座 邮编：100031 [Table_Title] STC007 二期临床数据读出，业务转型阶段把 握价值重估机遇 [Table_ReportDate] 2025 年 06 月 04 日 [Table_S 事件：2025ummar年y]5 月 29 日，公司公告全资子公司诺和晟泰自主研发的 STC007 注射液治疗腹部手术后的中、重度疼痛的 II 期临床试验达成预期目标。 点评： ➢ STC007 二期临床数据读出，具备较强的商业化潜力。 STC007 是诺和晟泰自主研发的化学 1 类新药，属于强效 KOR 激动剂， 与 KOR 受 ...

上 市 公 司 美容护理 2025 年 06 月 04 日 诺邦股份 (603238) ——个护家清行业机遇期，高端水刺无纺布打开成长空间 报告原因：首次覆盖 买入（首次评级） | 市场数据： | 2025 年 06 月 03 日 | | --- | --- | | 收盘价（元） | 16.05 | | 一年内最高/最低（元） | 20.61/8.70 | | 市净率 | 2.0 | | 股息率%（分红/股价） | 1.87 | | 流通 A 股市值（百万元） | 2,849 | | 上证指数/深证成指 | 3,361.98/10,057.17 | 注："股息率"以最近一年已公布分红计算 | 基础数据: | 2025 年 03 月 31 日 | | --- | --- | | 每股净资产（元） | 8.06 | | 资产负债率% | 41.11 | | 总股本/流通 A 股（百万） | 178/178 | | 流通 B 股/H 股（百万） | -/- | 一年内股价与大盘对比走势： 06-03 07-03 08-03 09-03 10-03 11-03 12-03 01-03 02-03 03-03 04-0 ...

Investment Rating - The report maintains a "Recommended" rating for the company, indicating a potential upside of over 15% relative to the benchmark index [8][27]. Core Views - The company has shown steady growth in its self-owned brand sales, with a significant increase in new energy vehicle (NEV) sales, which rose by 69.9% year-on-year in May [4][5]. - The company aims to achieve a total sales target of 3 million vehicles and 1 million NEVs by 2025, supported by the launch of new models [4][5]. - The report highlights the company's strong performance in overseas markets, with plans to establish new operational entities and logistics nodes globally [6]. Summary by Sections Sales Performance - In May, the company reported a wholesale volume of 224,000 vehicles, a year-on-year increase of 8.5% and a month-on-month increase of 17.6%. Cumulative sales from January to May reached 1.12 million vehicles, up 1.0% year-on-year [3]. - The self-owned brand sales in May were 185,000 vehicles, reflecting an 8.0% increase year-on-year and a 21.6% increase month-on-month [3]. New Energy Vehicles - The NEV sales in May reached 95,000 units, marking a 69.9% increase year-on-year, with cumulative sales from January to May at 351,000 units, up 46.9% year-on-year [4]. - The deep blue brand sold 26,000 units in May, a year-on-year increase of 77.6%, while the Avita brand saw sales of 12,767 units, up 179.4% year-on-year [4][5]. Future Outlook - The company plans to launch several new models, including the Deep Blue intelligent sports sedan and the Qiyuan C390, to enhance its product lineup and accelerate its electrification transition [4]. - The report projects revenues of 189.6 billion, 209.5 billion, and 233.5 billion yuan for 2025, 2026, and 2027 respectively, with net profits expected to be 88.7 billion, 107.6 billion, and 127.2 billion yuan [6][7]. Global Expansion - The company achieved overseas sales of 44,835 vehicles in May, with a total of 247,000 units sold from January to May [6]. - Plans for 2025 include establishing eight new operational entities and 16 logistics nodes globally, with a focus on expanding the Deep Blue and Avita brands in international markets [6].

北交所信息更新 北 交 所 研 究 捷众科技（873690.BJ） 2025 年 06 月 04 日 投资评级：增持（维持） | 日期 | 2025/6/3 | | --- | --- | | 当前股价(元) | 24.62 | | 一年最高最低(元) | 31.15/10.10 | | 总市值(亿元) | 16.32 | | 流通市值(亿元) | 7.54 | | 总股本(亿股) | 0.66 | | 流通股本(亿股) | 0.31 | | 近 3 个月换手率(%) | 376.46 | 北交所研究团队 诸海滨（分析师） zhuhaibin@kysec.cn 证书编号：S0790522080007 2024 年营收 2.86 亿元，同比+24%；归母净利润 6251 万元，同比+57% 公司发布 2024 年报与 2025 年一季报，2024 年，公司实现营收 2.86 亿元，同比 增长 23.63%，归母净利润 6251.14 万元，同比增长 56.86%；2025Q1，公司实现 营收7291.21亿元，同比增长44.24%，归母净利润1352.03万元，同比下滑15.49%， 扣非归母净利润 1296. ...

Investment Rating - The investment rating for Ping An Insurance (601318) is "Buy" (maintained) [2][7] Core Views - On June 4, Ping An announced the issuance of HKD 11.765 billion convertible bonds to support capital needs and strategic development in healthcare and elderly care [2] - The issuance of convertible bonds is expected to enhance the company's capital strength at a lower cost, optimizing the capital structure and supporting business development [7] - The report maintains previous profit forecasts, expecting net profit attributable to shareholders to be CNY 135.2 billion, CNY 154.4 billion, and CNY 177.0 billion for 2025, 2026, and 2027 respectively [7] Financial Forecasts - Total revenue (CNY million) is projected to be 913,789 in 2023, 1,028,925 in 2024, and expected to grow to 1,215,854 by 2027, with a CAGR of 6.9% from 2024 to 2027 [7][9] - Net profit attributable to shareholders (CNY million) is forecasted to decline by 22.8% in 2023, followed by a significant recovery of 47.8% in 2024, and steady growth of 6.8%, 14.2%, and 14.6% in the subsequent years [7][9] - The estimated PEV for 2025 is 0.65x, indicating that the current market valuation remains low [7][9] Market Data - The closing price of Ping An is CNY 53.85, with a market capitalization of CNY 980.62 billion [5] - The price-to-book ratio (P/B) is 1.04, and the price-to-earnings ratio (P/E) is projected to be 7.75 for 2024 [5][9] Capital Adequacy - As of Q1 2025, the core solvency ratio for Ping An Life is 163.7%, and the comprehensive solvency ratio is 227.9%, reflecting a significant increase from the beginning of the year [7]